TheraRadar
← Back
Data updated: Jun 28, 2026

MAYNE PHARMA COMMRCL

Pharma

MAYNE PHARMA COMMRCL is a pharmaceutical company focused on Oncology.

2005
Since
1
Drugs
-
Trials
0
New Drugs (2yr)
Modality:
1 Small Molecules

MAYNE PHARMA COMMRCL's Key Drugs

MAYNE PHARMA COMMRCL's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

MAYNE PHARMA COMMRCL's Recent FDA Approvals

New NDA/BLA approvals for MAYNE PHARMA COMMRCL over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

MAYNE PHARMA COMMRCL's Therapeutic Areas

MAYNE PHARMA COMMRCL's approved drugs and pipeline span 1 therapeutic area, led by Oncology, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 100%
1 drugs

MAYNE PHARMA COMMRCL's Top Competitors

MAYNE PHARMA COMMRCL's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Novartis, and Merck. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

MAYNE PHARMA COMMRCL Pipeline Snapshot

Active clinical trials for MAYNE PHARMA COMMRCL across all therapeutic areas, from ClinicalTrials.gov.

No active pipeline data available

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • Top drug revenue breakdown
  • Drug-level revenue analysis

Trial Catalysts

  • Oncology pipeline focus
  • Phase 3 readout tracking

Patent Risk

  • Patent expiration timeline
  • Revenue at risk analysis

Compare Companies

  • Side-by-side pipeline analysis
  • Revenue & market share comparison
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling